Advanced Nanocarriers for Targeted Drug and Gene Delivery

Topic Information

Dear Colleague,

Advanced nanocarriers represent a cutting-edge method for conducting precision medicine, being capable of targeting and delivering drugs and genetic materials to specific cells or tissues while minimizing off-target effects.  These nanosystems, based on polymeric, lipid or inorganic nanoparticles, include liposomes, polymeric nanoparticles and micelles, dendritic macromolecules, DNA nanostructures and exosomes. Nanocarriers are designed to enhance bioavailability, improve pharmacokinetics and overcome biological barriers, such as the blood–brain barrier or the tumor microenvironment. Therefore, advanced nanocarriers hold great promise for revolutionizing the processes of drug and gene delivery, offering the potential to improve the treatment of a wide range of diseases, including cancer; infectious, neurodegenerative and genetic diseases; and genetic disorders, with the possibility of being used to create personalized treatment strategies. However, challenges in scalability, biocompatibility and long-term safety still exist, driving continuous research on the design and transformation of nanomaterials. Potential topics include, but are not limited to, the following: 

• Nanocarrier Design and Optimization: Tailoring nanocarrier properties (size, shape, surface chemistry) and incorporating targeting ligands (e.g., antibodies, peptides, aptamers) to enhance cellular uptake and specificity.
• Stimuli-Responsive Systems: Facilitating pH-, redox-, or enzyme-triggered release for spatiotemporal control.
• Active and Passive Targeting: Ligand-functionalized carriers for receptor-mediated uptake (e.g., in cancer or inflamed tissues).
• Gene Delivery: Non-viral vectors (e.g., cationic polymers, lipid nanoparticles) for CRISPR, siRNA or mRNA delivery.
• Barrier Penetration: Strategies to cross the blood–brain barrier or tumor stroma.
• Applications of Nanocarriers: Spanning oncology, neurology and regenerative medicine, with an emerging focus on personalized nanomedicine and combination therapies.
• Multifunctional Nanocarriers: Integration of multiple functionalities into nanocarriers to enhance their theranostic capabilities (diagnosis and therapy).
• Translational Challenges: Scalability, biocompatibility and regulatory hurdles for their clinical adoption.

Dr. Rita Cortesi
Dr. Maddalena Sguizzato
Dr. Francesca Ferrara
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Biomolecules biomolecules	4.8	9.2	2011	19.4 Days	CHF 2700	Submit
Molecules molecules	4.6	8.6	1996	16.1 Days	CHF 2700	Submit
Nanomaterials nanomaterials	4.3	9.2	2010	15.4 Days	CHF 2400	Submit
Onco onco	-	-	2021	20.7 Days	CHF 1000	Submit
Pharmaceutics pharmaceutics	5.5	10.0	2009	14.9 Days	CHF 2900	Submit
Cancers cancers	4.4	8.8	2009	20.3 Days	CHF 2900	Submit
Applied Nano applnano	-	4.6	2020	14.8 Days	CHF 1000	Submit
Antioxidants antioxidants	6.6	12.4	2012	17.4 Days	CHF 2900	Submit

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers